Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback